Phase II Trial of Natalizumab (Tysabri) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Phase of Trial: Phase II
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Natalizumab (Primary) ; Methylprednisolone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 02 Jul 2019 Status changed from active, no longer recruiting to completed.
- 28 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2017 Results (n=18) assessing safety and efficacy presented at the 59th Annual Meeting and Exposition of the American Society of Hematology